Teneligliptin Hydrobromide Intermediate CAS 401564-36-1 Purity >99.5% (HPLC) Factory
Ugavi Vianzi Vinavyohusiana vya Teneligliptin Hydrobromide Kwa Usafi wa Hali ya Juu
Teneligliptin Hydrobromide CAS 906093-29-6
1-(3-Methyl-1-Phenyl-5-Pyrazolyl)piperazine CAS 401566-79-8
Teneligliptin Hydrobromide ya Kati CAS 401564-36-1
Jina la Kemikali | (2S)-4-Oxo-2-(3-thiazolidinylcarbonyl)-1-pyrrolidinecarboxylic acid tert-butyl ester |
Visawe | (S)-tert-Butyl 4-oxo-2-(thiazolidine-3-carbonyl)pyrrolidine-1-carboxylate;3-((S) -1-tert-butoxycarbonyl-4-oxo-2-pyrrolidinylcarbonyl) -1,3-thiazolidine;(2S) -4-oxo-2-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidine-1-carboxylate;Teneligptin ya kati B |
Nambari ya CAS | 401564-36-1 |
Nambari ya CAT | RF-1818 |
Hali ya Hisa | Katika Hisa, Uzalishaji Umeongezeka Hadi Tani |
Mfumo wa Masi | C13H20N2O4S |
Uzito wa Masi | 300.37 |
Msongamano | 1.305 |
Chapa | Ruifu Chemical |
Kipengee | Kiwango cha Ukaguzi | Matokeo |
Mwonekano | Nyeupe hadi Cream Rangi Imara | Kukubaliana |
Utambulisho | IR;HPLC RT | Kukubaliana |
Kupoteza kwa Kukausha | <1.00% | 0.20% |
Dutu Zinazohusiana | Uchafu Wowote Mmoja <0.50% | 0.24% |
Uchafu Jumla <0.50% | 0.39% | |
Uchambuzi | 99.5%~102.0% (Kwa Msingi Mkavu) | 99.8% |
Usafi wa Enantiomeri | >99.5% | 99.9% |
Majivu yenye Sulphated | <0.20% | 0.02% |
Kiwango cha Mtihani | Kiwango cha Biashara | |
Matumizi | Viungo vya kati vya Teneligliptin Hydrobromide (CAS: 906093-29-6) |
Kifurushi: Chupa, begi ya karatasi ya Alumini, Ngoma ya 25kg/Cardboard, au kulingana na mahitaji ya mteja
Hali ya Uhifadhi:Hifadhi kwenye vyombo vilivyofungwa mahali pa baridi na kavu;Kinga kutoka kwa mwanga na unyevu
![1](https://a395.goodao.net/uploads/15.jpg)
![](https://a395.goodao.net/uploads/23.jpg)
(2S)-4-Oxo-2-(3-thiazolidinylcarbonyl)-1-pyrrolidinecarboxylic acid tert-butyl ester (CAS: 401564-36-1) ni cha kati kinachotumika kuandaa kizuizi cha dipeptidyl peptidase IV (DPP-IV), cha kati. ya Teneligliptin Hydrobromide (CAS: 906093-29-6).Teneligliptin ni kizuizi cha DPP-4 ambacho kiliidhinishwa nchini Japani mnamo 2012 kwa matibabu ya ugonjwa wa kisukari cha aina ya II.Iligunduliwa na kuendelezwa na Mitsubishi Tanabe Pharma chini ya jina la biashara la Tenelia®.Sawa na vizuizi vingine vya DPP-4 vilivyouzwa, Teneligliptin ilivumiliwa vyema katika tafiti zote na kipimo cha QD kilizalisha hatua ya muda mrefu ya kizuizi dhidi ya DPP-4 na kuongezeka kwa viwango vya kazi vya GLP-1, na viwango vya chini sana vya utolewaji wa figo.